Moneycontrol PRO
HomeNewsIndiaCOVID-19 vaccine for children | Clinical trials may begin in India by mid-2021: Report

COVID-19 vaccine for children | Clinical trials may begin in India by mid-2021: Report

The Pfizer vaccine authorised in the United Kingdom and the United States is for people of age 16 years and older.

December 22, 2020 / 10:13 IST
A child wearing a protection mask and gloves is seen at Indira Gandhi International (IGI) airport. (Image: Reuters)

Amid the growing COVID-19 cases and emerging new coronavirus strain, the vaccine against COVID-19 promises a return to normal in the not-so-distant future. For people aged 16 years and above, the vaccine shot has been developed.

While the elderly are a high-risk group and on the list of people to receive the COVID-19 vaccine after health care workers and frontline staff, what about the youngest members of society – children? Vaccine manufacturers in the race to develop the vaccine against the contagion believe that progress on paediatric versions is not far behind, Business Standard reported quoting sources.

“Once the immunisation programme starts and one can observe the vaccines in use on a mass-scale, the safety of these investigational products would be established beyond doubt. It is around the middle of the next year that one would plan to start clinical trials for children,” a leading vaccine maker, which is in the final leg of developing a COVID-19 vaccine, told the publication.

The Pfizer vaccine authorised in the United Kingdom and the United States is for people of age 16 years and older. Also, testing began in October in children as young as 12 and is expected to take several more months.

Moderna, which has become the second COVID-19 vaccine to get greenlit in the US, began enrolling study participants ages 12 to 17 this month, and will track them for a year. Testing in children younger than 12 is expected to start in early 2021.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

It is uncertain if the results on younger children will come in time for vaccinations to begin before the next school year.

Positive outcomes in adult studies are reassuring and suggest it is safe to proceed in testing kids, said Dr. Buddy Creech, a pediatric infectious disease specialist at Vanderbilt University and director of its vaccine research program.

Even though children usually do not get very sick from COVID-19, they can spread the virus to others, said Dr Robert Frenck, who is the lead researcher for Pfizer’s study in kids at Cincinnati Children’s Hospital.

(With inputs from agencies)

Follow our full coverage on COVID-19 here.

Moneycontrol News
first published: Dec 22, 2020 10:13 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347